

STN-Structure Search

10/25/07

10/561,338

=> d ibib abs hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1042052 CAPLUS
 DOCUMENT NUMBER: 143:319142
 TITLE: Methods for treating inflammatory and autoimmune diseases using inhibitors of VEGF and nitric oxide
 INVENTOR(S): Chang, Yung; Lorton, Dianne; Lubahn, Cheri; Pettit, George R.; Wilson, David; Ananieva, Olga
 PATENT ASSIGNEE(S): The Arizona Board of Regents, On Behalf of Arizona State University, USA; Sun Health Research Institute
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089736	A2	20050929	WO 2005-US7011	20050304
WO 2005089736	A3	20051208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005261246	A1	20051124	US 2005-71994	20050304
EP 1720552	A2	20061115	EP 2005-724535	20050304
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2004-550759P	P 20040305
			US 2004-553189P	P 20040315
			US 2004-587928P	P 20040714
			US 2004-589109P	P 20040719
			WO 2005-US7011	W 20050304

AB The present invention provides methods for treating inflammatory conditions, rheumatoid diseases, autoimmune conditions, and conditions associated with bone loss, comprising administering to a subject with an inflammatory condition an effective amount of inhibitors of VEGF and NO, i.e., a compound selected from the group consisting of narcistatin, pancratistatin, pancratistatin 7'-phosphate and pancratistatin 3',4'-cyclic phosphate, or pharmaceutically acceptable salts thereof. Thus, sodium narcistatin i.p. injection (5 mg/kg/day) given once-daily reduced hind limb inflammation (-70%) and bone loss (-50%) in rats with adjuvant-induced arthritis (AA), compared to vehicle treated AA rats.

IT 687635-66-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nitric oxide and VEGF inhibitors for treating inflammatory and autoimmune diseases)

RN 687635-66-1 CAPLUS
 CN 1,3,2-Dioxaphospholo[4,5-c][1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one, 3b,4,10b,11,12,12a-hexahydro-2,6,11,12-tetrahydroxy-, 2-oxide, (3aS,3bR,10bR,11R,12S,12aR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




Inventor

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:76238 CAPLUS
 DOCUMENT NUMBER: 142:176985
 TITLE: Preparation and Phosphorylation of Phenpanstatin and Pancreatistatin as antitumor agents
 INVENTOR(S): Pettit, George R.; Melody, Noeleen
 PATENT ASSIGNEE(S): Arizona Board of Regents A Body Corporate of the State of Arizone, Acting for and On Behalf of Arizona State University, USA
 SOURCE: PCT Int. Appl., 35 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007084	A2	20050127	WO 2004-US19725	20040618
WO 2005007084	A3	20050224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1644001	A2	20060412	EP 2004-776823	20040618
R: DE, FR, GB				
US 2006128668	A1	20060615	US 2005-561338	20051215
PRIORITY APPLN. INFO.:			US 2003-480291P	P 20030620
			WO 2004-US19725	W 20040618

OTHER SOURCE(S): CASREACT 142:176985
 GI



- AB Selective phosphorylation of phenpanstatin with tetrabutylammonium dihydrogen phosphate and dicyclohexylcarbodiimide in pyridine followed by cation-exchange chromatog. procedures was found to provide an efficient route to a new series I (X = Na, Li, K) of promising 3,4-O-cyclic phosphate prodrugs designated phenpanstatin phosphates. Application of analogous reaction conditions to pancratistatin led to a mixture of monophosphate derivs. where sodium pancratistatin 4-O-phosphate was isolated and the structure confirmed by X-ray crystallog. Modification of the reaction conditions allowed direct phosphorylation of pancratistatin followed by cation-exchange chromatog. to afford sodium pancratistatin 3,4-O-cyclic phosphate II (X = Na), which was selected for pre-clin. development.
- IT 670258-01-2P, Sodium pancratistatin 3,4-cyclic phosphate
 670258-14-7P, Sodium phenpanstatin 3,4-cyclic phosphate
 RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and anticancer activity of phenpanstatin and pancratistatin phosphates)
- RN 670258-01-2 CAPPLUS
- CN 1,3,2-Dioxaphospholo[4,5-c] [1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one, 3b,4,10b,11,12,12a-hexahydro-2,6,11,12-tetrahydroxy-, 2-oxide, monosodium salt, (3aS,3bR,10bR,11R,12S,12aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



● Na

- RN 670258-14-7 CAPPLUS
- CN 1,3,2-Dioxaphospholo[4,5-c] [1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one, 11-(benzoyloxy)-3b,4,10b,11,12,12a-hexahydro-2,6,12-trihydroxy-, 2-oxide, monosodium salt, (3aS,3bR,10bR,11R,12S,12aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



● Na

- IT 671216-82-3P, Lithium phenpastatin 3,4-cyclic phosphate
 671216-83-4P, Potassium phenpastatin 3,4-cyclic phosphate
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (preparation and anticancer activity of phenpanstatin and pancratistatin phosphates)
- RN 671216-82-3 CAPLUS
- CN 1,3,2-Dioxaphospholo[4,5-c] [1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one,
 11-(benzoyloxy)-3b,4,10b,11,12,12a-hexahydro-2,6,12-trihydroxy-, 2-oxide,
 monolithium salt, (3aS,3bR,10bR,11R,12S,12aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



● Li

- RN 671216-83-4 CAPLUS
- CN 1,3,2-Dioxaphospholo[4,5-c] [1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one,
 11-(benzoyloxy)-3b,4,10b,11,12,12a-hexahydro-2,6,12-trihydroxy-, 2-oxide,
 monopotassium salt, (3aS,3bR,10bR,11R,12S,12aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● K


IT 671216-80-1P' 671216-81-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and anticancer activity of phenpanstatin and pancratistatin phosphates)

RN 671216-80-1 CAPPLUS

CN 1,3,2-Dioxaphospholo[4,5-c][1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one,
3b,4,10b,11,12,12a-hexahydro-2,6,11,12-tetrahydroxy-, 2-oxide, monolithium
salt, (3aS,3bR,10bR,11R,12S,12aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● Li

RN 671216-81-2 CAPPLUS


CN 1,3,2-Dioxaphospholo[4,5-c][1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one,
3b,4,10b,11,12,12a-hexahydro-2,6,11,12-tetrahydroxy-, 2-oxide,
monopotassium salt, (3aS,3bR,10bR,11R,12S,12aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● K

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:42453 CAPLUS
 DOCUMENT NUMBER: 140:253742
 TITLE: Antineoplastic Agents. 511. Direct Phosphorylation of Phenpanstatin and Pancratistatin
 Pettit, George R.; Melody, Noeleen; Herald, Delbert L.
 Cancer Research Institute and Department of Chemistry and Biochemistry, Arizona State University, Tempe, AZ, 85287-2404, USA
 AUTHOR(S):
 CORPORATE SOURCE:
 SOURCE: Journal of Natural Products (2004), 67(3), 322-327
 CODEN: JNPRDF; ISSN: 0163-3864
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:253742
 GI




AB Selective phosphorylation of phenpanstatin with tetrabutylammonium dihydrogen phosphate and dicyclohexylcarbodiimide in pyridine followed by cation-exchange chromatog. procedures was found to provide an efficient route to a new series I ($X = \text{Na, Li, K}$) of promising 3,4-O-cyclic phosphate prodrugs designated phenpanstatin phosphates. Application of analogous reaction conditions to pancratistatin led to a mixture of monophosphate derivs. where sodium pancratistatin 4-O-phosphate was isolated and the structure confirmed by X-ray crystallog. Modification of the reaction conditions allowed direct phosphorylation of pancratistatin followed by cation-exchange chromatog. to afford sodium pancratistatin 3,4-O-cyclic phosphate II ($X = \text{Na}$), which was selected for preclin.

development.

- IT 670258-01-2P, Sodium pancratistatin 3,4-cyclic phosphate
 670258-14-7P, Sodium phenpastatin 3,4-cyclic phosphate
 RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and anticancer activity of phenpanstatin and pancratistatin phosphates)
- RN 670258-01-2 CAPPLUS
- CN 1,3,2-Dioxaphospholo[4,5-c] [1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one,
 3b,4,10b,11,12,12a-hexahydro-2,6,11,12-tetrahydroxy-, 2-oxide, monosodium salt, (3aS,3bR,10bR,11R,12S,12aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



● Na

- RN 670258-14-7 CAPPLUS
 CN 1,3,2-Dioxaphospholo[4,5-c] [1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one,
 11-(benzoyloxy)-3b,4,10b,11,12,12a-hexahydro-2,6,12-trihydroxy-, 2-oxide,
 monosodium salt, (3aS,3bR,10bR,11R,12S,12aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Na


- IT 671216-82-3P, Lithium phenpastatin 3,4-cyclic phosphate
 671216-83-4P, Potassium phenpastatin 3,4-cyclic phosphate
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)

(preparation and anticancer activity of phenpanstatin and pancratistatin phosphates)

RN 671216-82-3 CAPLUS

CN 1,3,2-Dioxaphospholo[4,5-c][1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one,
11-(benzoyloxy)-3b,4,10b,11,12,12a-hexahydro-2,6,12-trihydroxy-, 2-oxide,
monolithium salt, (3aS,3bR,10bR,11R,12S,12aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● Li

RN 671216-83-4 CAPLUS

CN 1,3,2-Dioxaphospholo[4,5-c][1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one,
11-(benzoyloxy)-3b,4,10b,11,12,12a-hexahydro-2,6,12-trihydroxy-, 2-oxide,
monopotassium salt, (3aS,3bR,10bR,11R,12S,12aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● K

IT 671216-80-1P 671216-81-2P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation and anticancer activity of phenpanstatin and pancratistatin phosphates)

RN 671216-80-1 CAPLUS

CN 1,3,2-Dioxaphospholo[4,5-c][1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one,
3b,4,10b,11,12,12a-hexahydro-2,6,11,12-tetrahydroxy-, 2-oxide, monolithium
salt, (3aS,3bR,10bR,11R,12S,12aR)- (9CI) (CA INDEX NAME)

10/561,338

Absolute stereochemistry. Rotation (-).




● Li

RN 671216-81-2 CAPLUS

CN 1,3,2-Dioxaphospholo[4,5-c] [1,3]dioxolo[4,5-j]phenanthridin-5(3aH)-one,
3b,4,10b,11,12,12a-hexahydro-2,6,11,12-tetrahydroxy-, 2-oxide,
monopotassium salt, (3aS,3bR,10bR,11R,12S,12aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● K

REFERENCE COUNT:

24

THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:22:12 ON 25 OCT 2007)

FILE 'REGISTRY' ENTERED AT 16:22:26 ON 25 OCT 2007

L1 STRUCTURE uploaded
L2 0 S L1
L3 8 S L1 FULL

FILE 'CAPLUS' ENTERED AT 16:22:57 ON 25 OCT 2007

L4 3 S L3


=> d l1

L1 HAS NO ANSWERS

10/561,338

L1

STR



Structure attributes must be viewed using STN Express query preparation.

=>

10/561,338

STN-structure Search
10/25/07


d ibib abs hitstr 1-2

OmniCat

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:76238 CAPLUS
 DOCUMENT NUMBER: 142:176985
 TITLE: Preparation and Phosphorylation of Phenpanstatin and Pancratistatin as antitumor agents
 INVENTOR(S): Pettit, George R.; Melody, Noeleen
 PATENT ASSIGNEE(S): Arizona Board of Regents A Body Corporate of the State of Arizona, Acting for and On Behalf of Arizona State University, USA
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007084	A2	20050127	WO 2004-US19725	20040618
WO 2005007084	A3	20050224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1644001	A2	20060412	EP 2004-776823	20040618
R: DE, FR, GB				
US 2006128668	A1	20060615	US 2005-561338	20051215
PRIORITY APPLN. INFO.:			US 2003-480291P	P 20030620
			WO 2004-US19725	W 20040618

OTHER SOURCE(S): CASREACT 142:176985
 GI




AB Selective phosphorylation of phenpanstatin with tetrabutylammonium dihydrogen phosphate and dicyclohexylcarbodiimide in pyridine followed by cation-exchange chromatog. procedures was found to provide an efficient route to a new series I (X = Na, Li, K) of promising 3,4-O-cyclic phosphate prodrugs designated phenpanstatin phosphates. Application of analogous reaction conditions to pancratistatin led to a mixture of monophosphate derivs. where sodium pancratistatin 4-O-phosphate was

10/561, 338

CM 1

CRN 670258-03-4
CMF C14 H16 N.O11 P


Absolute stereochemistry.



CM 2

CRN 56-54-2
CMF C20 H24 N2 O2

Absolute stereochemistry. Rotation (+).



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:42453 CAPLUS

DOCUMENT NUMBER: 140:253742

TITLE: Antineoplastic Agents. 511. Direct Phosphorylation of Phenpanstatin and Pancratistatin

AUTHOR(S): Pettit, George R.; Melody, Noeleen; Herald, Delbert L.
CORPORATE SOURCE: Cancer Research Institute and Department of Chemistry
and Biochemistry, Arizona State University, Tempe, AZ,
85287-2404, USA

SOURCE: Journal of Natural Products (2004), 67(3), 322-327
CODEN: JNPRDF; ISSN: 0163-3864


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:253742

GI




AB Selective phosphorylation of phenpanstatin with tetrabutylammonium dihydrogen phosphate and dicyclohexylcarbodiimide in pyridine followed by cation-exchange chromatog. procedures was found to provide an efficient route to a new series I ($X = \text{Na}, \text{Li}, \text{K}$) of promising 3,4-O-cyclic phosphate prodrugs designated phenpanstatin phosphates. Application of analogous reaction conditions to pancratistatin led to a mixture of monophosphate derivs. where sodium pancratistatin 4-O-phosphate was isolated and the structure confirmed by X-ray crystallog. Modification of the reaction conditions allowed direct phosphorylation of pancratistatin followed by cation-exchange chromatog. to afford sodium pancratistatin 3,4-O-cyclic phosphate II ($X = \text{Na}$), which was selected for preclin. development.

IT 670258-00-1P, Sodium pancratistatin 4-O-phosphate
RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (crystal structure; preparation and anticancer activity of phenpanstatin and pancratistatin phosphates)

RN 670258-00-1 CAPLUS

CN [1,3]Dioxolo[4,5-j]phenanthridin-6(2H)-one, 1,3,4,4a,5,11b-hexahydro-1,2,3,7-tetrahydroxy-4-(phosphonoxy)-, monosodium salt,
 $(1R,2S,3R,4S,4aR,11bR)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na


IT 670258-03-4P, Pancratistatin 4-O-phosphoric acid
RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and anticancer activity of phenpanstatin and pancratistatin phosphates)

10/561, 338

RN 670258-03-4 CAPLUS

CN [1,3]Dioxolo[4,5-j]phenanthridin-6(2H)-one, 1,3,4,4a,5,11b-hexahydro-1,2,3,7-tetrahydroxy-4-(phosphonoxy)-, (1R,2S,3R,4S,4aR,11bR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 670258-04-5P, Lithium pancratistatin 4-O-phosphate

670258-05-6P, Potassium pancratistatin 4-O-phosphate

670258-06-7P, Magnesium pancratistatin 4-O-phosphate

670258-07-8P, Calcium pancratistatin 4-O-phosphate

670258-08-9P, Zinc pancratistatin 4-O-phosphate

670258-09-0P, Piperazinium pancratistatin 4-O-phosphate

670258-10-3P, Morpholinium pancratistatin 4-O-phosphate

670258-11-4P 670258-12-5P, Quininium pancratistatin

4-O-phosphate 670258-13-6P, Quinidinium pancratistatin

4-O-phosphate

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);

BIOL (Biological study); PREP (Preparation)

(preparation and anticancer activity of phenpanstatin and pancratistatin phosphates)


RN 670258-04-5 CAPLUS

CN [1,3]Dioxolo[4,5-j]phenanthridin-6(2H)-one, 1,3,4,4a,5,11b-hexahydro-

1,2,3,7-tetrahydroxy-4-(phosphonoxy)-, monolithium salt,

(1R,2S,3R,4S,4aR,11bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li


RN 670258-05-6 CAPLUS

CN [1,3]Dioxolo[4,5-j]phenanthridin-6(2H)-one, 1,3,4,4a,5,11b-hexahydro-1,2,3,7-tetrahydroxy-4-(phosphonoxy)-, monopotassium salt,

10/561, 338

(1R,2S,3R,4S,4aR,11bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● K

RN 670258-06-7 CAPLUS

CN [1,3]Dioxolo[4,5-j]phenanthridin-6(2H)-one, 1,3,4,4a,5,11b-hexahydro-1,2,3,7-tetrahydroxy-4-(phosphonoxy)-, magnesium salt (1:1),
(1R,2S,3R,4S,4aR,11bR)- (CA INDEX NAME)

Absolute stereochemistry.




● Mg

RN 670258-07-8 CAPLUS

CN [1,3]Dioxolo[4,5-j]phenanthridin-6(2H)-one, 1,3,4,4a,5,11b-hexahydro-1,2,3,7-tetrahydroxy-4-(phosphonoxy)-, calcium salt (1:1),
(1R,2S,3R,4S,4aR,11bR)- (CA INDEX NAME)

Absolute stereochemistry.




● Ca

RN 670258-08-9 CAPLUS

CN [1,3]Dioxolo[4,5-j]phenanthridin-6(2H)-one, 1,3,4,4a,5,11b-hexahydro-1,2,3,7-tetrahydroxy-4-(phosphonoxy)-, zinc salt (1:1),
(1R,2S,3R,4S,4aR,11bR)- (CA INDEX NAME)

Absolute stereochemistry.



● Zn

RN 670258-09-0 CAPLUS

CN [1,3]Dioxolo[4,5-j]phenanthridin-6(2H)-one, 1,3,4,4a,5,11b-hexahydro-1,2,3,7-tetrahydroxy-4-(phosphonoxy)-, (1R,2S,3R,4S,4aR,11bR)-, compd. with piperazine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 670258-03-4

CMF C14 H16 N O11 P


Absolute stereochemistry.

10/561, 338



CM 2

CRN 110-85-0
CMF C4 H10 N2




RN 670258-10-3 CAPLUS
CN [1,3]Dioxolo[4,5-j]phenanthridin-6(2H)-one, 1,3,4,4a,5,11b-hexahydro-1,2,3,7-tetrahydroxy-4-(phosphonoxy)-, (1R,2S,3R,4S,4aR,11bR)-, compd. with morpholine (1:1) (CA INDEX NAME)

CM 1

CRN 670258-03-4
CMF C14 H16 N O11 P


Absolute stereochemistry.



CM 2

CRN 110-91-8
CMF C4 H9 N O

10/561, 338



RN 670258-11-4 CAPLUS


CN [1,3]Dioxolo[4,5-j]phenanthridin-6(2H)-one, 1,3,4,4a,5,11b-hexahydro-1,2,3,7-tetrahydroxy-4-(phosphonoxy)-, (1R,2S,3R,4S,4aR,11bR)-, compd. with 4,5-dihydro-1H-imidazole (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 670258-03-4

CMF C14 H16 N O11 P


Absolute stereochemistry.



CM 2

CRN 504-75-6

CMF C3 H6 N2



RN 670258-12-5 CAPLUS


CN Cinchonan-9-ol, 6'-methoxy-, (8 α ,9R)-, compd. with (1R,2S,3R,4S,4aR,11bR)-1,3,4,4a,5,11b-hexahydro-1,2,3,7-tetrahydroxy-4-(phosphonoxy) [1,3]dioxolo[4,5-j]phenanthridin-6(2H)-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 670258-03-4

CMF C14 H16 N O11 P


Absolute stereochemistry.



CM 2

CRN 130-95-0
CMF C20 H24 N2 O2

Absolute stereochemistry.




RN 670258-13-6 CAPLUS
CN Cinchonan-9-ol, 6'-methoxy-, (9S)-, compd. with (1R,2S,3R,4S,4aR,11bR)-
1,3,4,4a,5,11b-hexahydro-1,2,3,7-tetrahydroxy-4-
(phosphonooxy) [1,3]dioxolo[4,5-j]phenanthridin-6(2H)-one (1:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 670258-03-4
CMF C14 H16 N O11 P

Absolute stereochemistry.




10/561,338

CM 2

CRN 56-54-2
CMF C20 H24 N2 O2

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:30:47 ON 25 OCT 2007)

FILE 'REGISTRY' ENTERED AT 16:30:53 ON 25 OCT 2007

L1 STRUCTURE uploaded
L2 1 S L1
L3 12 S L1 FULL


FILE 'CAPLUS' ENTERED AT 16:31:24 ON 25 OCT 2007

L4 2 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

10/561,338

=>